Skip to main content
OpenTrials
Completed

NCT Number: NCT05202873

Analysis of Spatiotemporal Gait Parameters in Patients With Megaprosthesis.

The main objective of the study is to evaluate spatiotemporal parameters of gait in tumoral patients with megaprosthesis of the distal femur.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universidad Ceu Cardenal Herrera

Valencia, 46006, Spain

About this study

Patients with distal femoral prostheses treated at La Fe Hospital in Valencia were evaluated and compared with healthy controls. A radiographic study was conducted in cases using telemetric imaging to assess the percentage of remaining bone and the long length limb discrepancy following surgical intervention. Additionally, a gait analysis was performed using the BTS device to obtain objective gait parameters. The gait assessment was conducted with a non-invasive portable device, the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy), which was placed at the S1 level to collect spatio-temporal gait data. The data were analyzed in relation to the values in healthy patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Megaprosthesis of the distal femur
  • Tumor cause
  • Surgery at Hospital la Fe.
  • Traditional stem or biological ossteointegration system
  • Minimum postoperative follow-up period of 3 months

Exclusion criteria

  • Neurological alterations prior to the intervention that affect the lower limbs or general movement.
  • Patient incapable of ambulation due to progression of his/her pathology
  • Patient at home with palliative treatment for advanced tumor disease
  • Any ipsilateral or contralateral prosthesis.
  • Infectious or traumatic cause

Treatment and study plan

Gait Analysis

Diagnostic Test

Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.

Primary outcomes

  1. Antero-posterior acceleration symmetry index

    Time frame: 3 months

    This metric serves as a quantifiable measure of the symmetry exhibited in movements along the antero-posterior axis, thereby illustrating the equilibrium and coordination inherent in the body's kinetic activities.

  2. Stance Phase

    Time frame: 3 months

    Refers to the portion of the gait cycle during which a foot is in contact with the ground. It begins with the initial contact (heel strike) and ends when the same foot leaves the ground (toe-off). The stance phase is a critical component of walking and running, contributing to balance, propulsion, and weight-bearing.

    Measured as a percentage of the total gait cycle, 60% of the cycle in typical walking.

  3. Swing Phase

    Time frame: 3 months

    Refers to the portion of the gait cycle during which a foot is not in contact with the ground. It begins when the foot lifts off the ground (toe-off) and ends when the same foot makes contact again (heel strike). The swing phase allows the leg to advance forward and position itself for the next step. Measured as a percentage of the total gait cycle, 40% of the cycle in normal walking.

  4. Gait Quality Index

    Time frame: 3 months

    The stance-swing phase ratio

  5. First Double support phase

    Time frame: 3 months

    Refers to the portion of the gait cycle during walking when both feet are in contact with the ground simultaneously. It occurs at the beginning of the stance phase for one leg, immediately after heel strike, and ends when the opposite foot lifts off (toe-off). This phase contributes to stability during gait. Measured as a percentage of the total gait cycle.

  6. Single Support Phase

    Time frame: 3 months

    Refers to the portion of the gait cycle during which only one foot is in contact with the ground bearing the entire body weight while the other foot is in the swing phase. It is essential for maintaining balance and forward progression during walking. Measured as a percentage of the total gait cycle.

  7. Propulsion Index

    Time frame: 3 months

    This measures the subject's ability to propel the centre of mass forward during the single support stance phase.

  8. Pelvic tilt range

    Time frame: 3 months

    Refers to the total angular movement of the pelvis in the sagittal plane during a specific activity, such as walking. It represents the difference between the maximum anterior tilt (forward rotation) and maximum posterior tilt (backward rotation) of the pelvis within a given cycle. Measured in degrees (°) to quantify the extent of pelvic rotation.

  9. Pelvic obliquity range

    Time frame: 3 months

    Refers to the total angular movement of the pelvis in the coronal (frontal) plane during activities such as walking. It describes the difference between the maximum upward tilt (hip hike) and maximum downward tilt (hip drop) of one side of the pelvis relative to the opposite side. Measured in degrees (°) to quantify the range of motion.

  10. Pelvic rotation range

    Time frame: 3 months

    Refers to the total angular movement of the pelvis in the transverse (horizontal) plane during activities such as walking. It represents the difference between the maximum forward rotation and maximum backward rotation of the pelvis around a vertical axis within a given cycle. Measured in degrees (°) to quantify the range of rotational motion.

  11. Pelvic symmetry tilt index

    Time frame: 3 months

    Is a quantitative measure that evaluates the symmetry of pelvic tilt during movement. It assesses the degree of deviation in pelvic tilt between the left and right sides in the sagittal plane, providing insight into potential imbalances or asymmetries. Expressed as a percentage (%) to indicate the level of symmetry.

  12. Pelvic symmetry obliquity index

    Time frame: 3 months

    Is a quantitative measure used to evaluate the symmetry of pelvic obliquity during movement. It quantifies the degree of deviation in upward or downward tilt of the pelvis on one side compared to the other in the coronal (frontal) plane, helping to identify potential imbalances or asymmetries. Expressed as a percentage (%) to represent the level of symmetry.

  13. Pelvic symmetry rotation index

    Time frame: 3 months

    Is a quantitative measure used to assess the symmetry of pelvic rotation during movement, particularly in the transverse (horizontal) plane. It calculates the difference in rotational movement between the left and right sides of the pelvis, helping to identify any imbalances or asymmetries in pelvic motion during activities like walking.Expressed as a percentage (%) to indicate the level of symmetry.

Secondary outcomes

  1. Bone remmant (%)

    Time frame: 3 months

    Bone remment respect a healthy femur in percentage (%)

  2. Long discrepancy (mm)

    Time frame: 3 months

    Long discrepancy in milimeters (mm) between healthy and tumoral leg. Positive discrepancy (tumoral leg longer) or negative discrepancy (tumoral leg shorter).

Sponsors and collaborators

Lead sponsor

Cardenal Herrera University

Other

Registry information

Official study title

Comparative Analysis of Spatiotemporal Gait Parameters in Patients With Distal Femoral Megaprosthesis and Healthy Subjects Using an Inertial Measurement Unit (IMU)

Acronym: MP-GP

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Jan 24, 2022
Registry last updated
Dec 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.